| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Globus Medical (NYSE:GMED) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.0, with a high estimate of $85.00 and a low estimate of $60.00. Marking an increase of 3.94%, the current average surpasses the previous average price target of $63.50.
The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt Miksic | Barclays | Raises | Overweight | $85.00 | $83.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $63.00 | $60.00 |
| Matt O'Brien | Piper Sandler | Raises | Neutral | $60.00 | $55.00 |
| Mathew Blackman | Stifel | Raises | Buy | $70.00 | $64.00 |
| Ryan Zimmerman | BTIG | Announces | Buy | $60.00 | - |
| Mathew Blackman | Stifel | Raises | Buy | $64.00 | $61.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $60.00 | $58.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Globus Medical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Globus Medical analyst ratings.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Globus Medical displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 124.6%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.37%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Globus Medical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GMED
